Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.

doi:10.1167/iovs.64.13.34

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.

Investigative ophthalmology & visual science - 3 Oct 2023

García-Quintanilla Laura, Almuiña-Varela Pablo, Maroñas Olalla, Gil-Rodriguez Almudena, Rodríguez-Cid María José, Gil-Martinez María, Abraldes Maximino J, Gómez-Ulla de Irazazabal Francisco, González-Barcia Miguel, Mondelo-Garcia Cristina, Cruz Raquel, Estany-Gestal Ana, Fernández-Rodríguez Maribel, Fernández-Ferreiro Anxo

Abstract excerpt

Purpose: To determine whether genetic risk single nucleotide polymorphisms (SNPs) for age-related macular degeneration (AMD) influence short-term response to intravitreal ranibizumab treatment. Methods: Forty-four treatment-naive AMD patients were included in a prospective observational study. They underwent three monthly injections of intravitreal ranibizumab for neovascular AMD. After an initial clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins E

Share to Intravitreal Injections

Share to Tomography, Optical Coherence

Share to Treatment Outcome

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Open in PubMed Open full text

Identifiers

PMID: 37862026
DOI: 10.1167/iovs.64.13.34
PMCID: PMC10599160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.PMID 37862026Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.Semantic proximity Read ↗

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Semantic proximity Read ↗

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.Semantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.Semantic proximity Read ↗

CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.